The Pharmaletter
Sandoz
Latest Sandoz News
Pharmaceutical
Merck & Co and Johnson & Johnson were pharma's big buyers in M&A during November. 2 December 2025
Related News
Insights
Company Spotlight
A TechBio company that specializes in developing personalized vaccines and immunotherapies through its advanced AI-Immunology™ platform. The company bridges artificial intelligence technology, bioinformatics, and drug development to bring novel immunotherapies to patients facing cancer and infectious diseases.
Latest News & Features of interest to Sandoz
Biotechnology
Link Cell Therapies, an oncology cell therapy company, has announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson. 15 December 2025
Biotechnology
One of the biggest challenges to the cell and gene therapy (CGT) landscape over the last couple of years has been the reduction in venture financing from $7.5 billion in 2021 to $3.3 billion in 2024. 15 December 2025
Biotechnology
California-based Tenaya Therapeutics, a biotech seeking to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, has announced the pricing of a $60 million public offering. 15 December 2025
Biotechnology
US biopharma Arcus Biosciences has announced the discontinuation of the Phase III STAR-221 study, being conducted in partnership with Gilead Sciences (Nasdaq: GILD), due to futility. 15 December 2025
Pharmaceutical
Japan’s Tanabe Pharma, formerly known as Mitsubishi Tanabe and now owned by Bain Capital, has obtained approval from the Ministry of Food and Drug Safety in South Korea to Radicut Suspension for the indication of amyotrophic lateral sclerosis. 15 December 2025
Biotechnology
M&A news last week featured Mirum Pharmaceuticals announcing plans to acquire fellow USA-based Bluejay Therapeutics and its kidney disease candidate brelovitug. The US Advisory Committee on Immunization Practices (ACIP) revealed changes to guidance on hepatitis B vaccination for newborns. On the research front, Swiss pharma giant Roche presented strong new data on its giredestrant in early breast cancer, while Rezolute released disappointing Phase III data on its congenital hyperinsulinism candidate ersodetug. 14 December 2025
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval at its December 2025 meeting. 13 December 2025
Pharmaceutical
British pharma major AstraZeneca has joined a near-$100 million series A and A+ financing round for Syneron Bio, a biotechnology startup focused on macrocyclic peptide therapies for oncology and chronic diseases. 12 December 2025
Pharmaceutical
New York, USA-based rare disease firm Applied Therapeutics has announced a definitive agreement to be acquired by privately-held UK-based Cycle Pharmaceuticals. 12 December 2025
Biotechnology
US pharma major Bristol Myers Squibb has announced progress for its multi-indication cancer drug Opdivo (nivolumab) in another oncology setting. 11 December 2025
Latest In Brief for Sandoz
Pharmaceutical
On December 12, 2025, the US Food and Drug Administration approved Johnson & Johnson subsidiary Janssen Biotech’s Akeega (niraparib and abiraterone acetate with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test. 15 December 2025
Latest Relevant Ones To Watch News
M&A news last week featured Mirum Pharmaceuticals announcing plans to acquire fellow USA-based Bluejay Therapeutics and its kidney disease candidate brelovitug. The US Advisory Committee on Immunization Practices (ACIP) revealed changes to guidance on hepatitis B vaccination for newborns. On the research front, Swiss pharma giant Roche presented strong new data on its giredestrant in early breast cancer, while Rezolute released disappointing Phase III data on its congenital hyperinsulinism candidate ersodetug. 14 December 2025
12 December 2025
8 December 2025
7 December 2025
7 December 2025
22 November 2025
20 November 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze